ライフサイエンスコーパス: anal cancer

1 ell carcinomas, gastroesophageal cancer, and anal cancer).

2 g men who have sex with men (MSM) and causes anal cancer.

3 -HPV infections, consistent with its role in anal cancer.

4 ximately 6-7 years prior to the diagnosis of anal cancer.

5 me a useful diagnostic tool in patients with anal cancer.

6 ablished prognostic factors in patients with anal cancer.

7 PV) 16 and 18 infections cause most cases of anal cancer.

8 y profile and may help to reduce the risk of anal cancer.

9 ce of anal HPV infections that contribute to anal cancer.

10 IV-1)-infected men are at increased risk for anal cancer.

11 ffect on local failure and colostomy rate in anal cancer.

12 usses the issues around screening to prevent anal cancer.

13 oplasia treatment to reduce the incidence of anal cancer.

14 als and recent studies on chemoradiation for anal cancer.

15 of intensity modulated radiation therapy for anal cancer.

16 dge conducted in chemotherapy-naive advanced anal cancer.

17 lesion (aHSIL) is the immediate precursor of anal cancer.

18 ous intraepithelial lesions (hHSIL) prevents anal cancer.

19 raepithelial lesions [HSIL]) associated with anal cancer.

20 men (GBM) are disproportionately affected by anal cancer.

21 risk for human papillomavirus (HPV)-related anal cancer.

22 are at increased risk for aHSIL and invasive anal cancer.

23 illomavirus (HPV)-related cancers, including anal cancer.

24 les were from the Study of the Prevention of Anal Cancer.

25 courage continuous international interest in anal cancer.

26 the screening, diagnosis, and prevention of anal cancer.

27 sk for human papillomavirus (HPV)-associated anal cancer.

28 methylation markers for detecting HGAIN and anal cancer.

29 s intraepithelial lesions (HSIL) and, hence, anal cancer.

30 ening and management of HIV+ MSM at risk for anal cancer.

31 with HIV infection have an elevated risk of anal cancer.

32 ponse evaluation after chemoradiotherapy for anal cancer.

33 icant role during posttreatment follow-up of anal cancer.

34 al adenocarcinoma, oropharyngeal cancer, and anal cancer.

35 vaccination and decrease in lifetime risk of anal cancer.

36 lysis to highlight discrepancies relevant to anal cancer.

37 life years, and lifetime risk of developing anal cancer.

38 used to record adverse events using PROs for anal cancer.

39 maviruses (HPVs) cause a large proportion of anal cancers.

40 ajor causative agents of cervical, oral, and anal cancers.

41 ver cancer and decreased for HL and lung and anal cancers.

42 ciated with approximately 90% of HPV-related anal cancers.

43 cers although no difference was observed for anal cancers.

44 o 90% of anal intraepithelial neoplasias and anal cancers.

45 (2.4%), KS (1.3%), liver cancer (1.1%), and anal cancer (0.6%).

46 e metastatic solid tumors (3 colon cancer, 1 anal cancer, 1 breast cancer, and 1 prostate cancer) age

47 , 4.5% and 0.7%; lung cancer, 3.4% and 2.8%; anal cancer, 1.5% and 0.05%; colorectal cancer, 1.0% and

48 y cervical (23% of the additional cases) and anal cancers (16%) in females and oropharyngeal cancers

49 These included anal cancer (23.8%; aOR, 2.94; 95% CI, 1.84-4.69), Hodgk

50 ial (37%), breast (31%), cervical (29%), and anal cancer (27%).

51 ta-standardised incidence ratio in PLHIV was anal cancer (37.28 [95% CI 23.65-58.75], I(2)=97.4%), an

52 te ratios of 3.85 (95% CI, 2.32 to 6.37) for anal cancer, 6.68 (95% CI, 3.64 to 12.25) for anal intra

53 squamous intraepithelial lesions (HSIL) and anal cancer (AC) compared with HIV-uninfected women.

54 We compared incidence rates of anal cancer across four calendar periods: 1992-1996 (pre

55 not recommended for patients with localized anal cancer.Additional information is available at

56 emoradiation became the standard of care for anal cancer after the ACT I trial.

57 ge independent cross-sectional series of 345 anal cancer, AIN3, AIN2, AIN1, and normal control biopsi

58 olution anoscopy (HRA) currently screens for anal cancer, although the definitive test remains unknow

59 esent the results of a case-control study of anal cancer among HIV-infected people in Switzerland.

60 The high incidence of anal cancer among HIV-positive individuals must not be i

61 An increasing incidence of anal cancer among men suggests a need to better understa

62 n, anal intraepithelial neoplasia (AIN), and anal cancer among people living with HIV.

63 Heterogeneity of risk for invasive anal cancer among PWH suggests the value of a shared dec

64 The prevalence of anal cancer among solid organ transplant recipients was

65 ssary to identify men at the highest risk of anal cancer among those infected with high-risk HPV.

66 good accuracy in posttreatment evaluation of anal cancer and has a relevant impact on patient managem

67 marker panel that includes ZNF582 identifies anal cancer and HGAIN with a cancer-like methylation pat

68 31, 2019, 1161 (43.6%) of 2662 patients with anal cancer and HIV and 7722 (35.4%) of 21 824 patients

69 Besides anal cancer and Hodgkin disease, the cohort studies have

70 All patients displayed squamous anal cancer and were treated with MMC alone or MMC plus

71 Most squamous cell anal cancers and precancerous lesions are attributed to

72 mous intraepithelial lesions (HSILs) precede anal cancer, and accurate studies of HSIL prevalence amo

73 study strengthens evidence that lung cancer, anal cancer, and myeloma are diagnosed at modestly young

74 ar, no history of genital warts or penile or anal cancer, and no current diagnosis of a sexually tran

75 esophageal, cervical, prostate, and possibly anal cancers; and since the 1990s for bone/joint and end

76 tudies of treatment for anal HSIL to prevent anal cancer are lacking.

77 de anal intraepithelial neoplasia to prevent anal cancer are warranted.

78 Most anal cancers are attributable to persistent human papill

79 llomavirus (HPV) is causally associated with anal cancer, as HPV DNA is detected in up to 90% of anal

80 As screening for anal cancer becomes more widespread, examining the effec

81 als aged 20-79 years diagnosed with invasive anal cancer between 2001 and 2019.

82 ity is relatively common before diagnosis of anal cancer but rare for other HPV-related anogenital ca

83 nodeficiency virus (HIV) have a high risk of anal cancer, but current screening strategies for HSIL d

84 tant at an early stage of the development of anal cancer, but that the neoplastic process becomes irr

85 ent for HGAIN decreased the lifetime risk of anal cancer by 63% compared with no vaccination.

86 high-grade anal intraepithelial neoplasia or anal cancer by history or by screening cytology or histo

87 A majority of anal cancer cases (73%) were men who have sex with men.

88 A case-control study that included 59 anal cancer cases and 295 individually matched controls

89 ation levels were assessed in a series of 10 anal cancer cases with preceding HGAIN at similar anatom

90 16 being implicated in the large majority of anal cancer cases.

91 papillomavirus (HPV) vaccination may prevent anal cancer caused by vaccine types.

92 igh-resolution anoscopy-guided ablation) and anal cancer (chemoradiation and possibly intensity-modul

93 seven of 24 individuals) who later developed anal cancer compared with 0.6% of controls (four of 718

94 ) are at increased risk of HPV infection and anal cancer compared with HIV-negative men.

95 with HIV are 19 times more likely to develop anal cancer compared with the general population.

96 The Study of the Prevention of Anal Cancer, conducted between 2010 and 2018, enrolled h

97 ) showed remarkable performance for AIN3 and anal cancer detection (area under the curve [AUC] > 0.85

98 Anal cancer developed in 33 of them.

99 To better understand anal cancer development and prevention, we determined wh

100 ed in MSM without HIV, increasing from 4% of anal cancer diagnosed at 30-44 years to 24% at >=60 year

101 appeared to be strongest 6-7 years prior to anal cancer diagnosis (OR for <200 vs. >/=500 cells/muL

102 The social stigma surrounding an anal cancer diagnosis has traditionally prevented open d

103 In the early stages, anal cancer does not exhibit evident symptoms.

104 The risk of anal cancer due to high-risk human papillomavirus (HR-HP

105 with all-cause mortality among patients with anal cancer, especially women.

106 We report the case of a 66-year-old anal cancer female patient presenting with an asymptomat

107 us (HIV)-infected women are at high risk for anal cancer, few data have been published on prevalence

108 400 cm(-1) between the control group and the anal cancer group related to the presence of proteins an

109 l cancer since no questionnaire specific for anal cancer has been developed.

110 The incidence of anal cancer has been increasing among U.S. women, yet fe

111 Recent studies show that the incidence of anal cancer has increased since the introduction of high

112 vical cancer; vaginal cancer; vulvar cancer; anal cancer; head and neck cancer; genital warts; and re

113 with increased cancer-specific mortality for anal cancer, Hodgkin lymphoma, or diffuse large B-cell l

114 an papillomavirus-related cancers, including anal cancer (HR, 2.77; 95% CI, 1.29-5.96) and female gen

115 ue to the heterogeneity of risk for invasive anal cancer (IAC) among people with human immunodeficien

116 dividuals were expected to be diagnosed with anal cancer in 2021.

117 The primary outcome was progression to anal cancer in a time-to-event analysis.

118 sk for Human papillomavirus (HPV)-associated anal cancer in comparison to men who have sex with women

119 ention of human papillomavirus (HPV)-induced anal cancer in high-risk populations such as human immun

120 he efficacy of screening programs to prevent anal cancer in HIV-1-infected subjects is unclear.

121 Treatment options for anal dysplasia and anal cancer in HIV-infected individuals are expanding an

122 that in the general population, the risk of anal cancer in HIV-infected patients is still extremely

123 y cancer, ovarian cancer, testicular cancer, anal cancer in male individuals, and Kaposi sarcoma in m

124 In the United States, anal cancer in men who have sex with men (MSM) is more c

125 5.9 (95% confidence interval, 3.4-10.3) for anal cancer in men.

126 of 30 and may explain the high incidence of anal cancer in MSM.

127 he efficacy of screening programs to prevent anal cancer in persons with human immunodeficiency virus

128 The incidence of anal cancer in the United States has recently increased,

129 ination may be useful for early detection of anal cancer in these populations.

130 eening might contribute to the prevention of anal cancer in women.

131 te intensity modulated radiation therapy for anal cancer, in an effort to reduce acute and long-term

132 0 cells per muL, there was a 40% decrease in anal cancer incidence (crude HR 0.60, 0.46-0.78; I(2) 21

133 Anal cancer incidence (per 100 000) among MSM without HI

134 cific statistics from multiple data sources (anal cancer incidence among all males; anal cancer incid

135 rces (anal cancer incidence among all males; anal cancer incidence among MSM and MSW with HIV; popula

136 ulation, used Poisson regression to evaluate anal cancer incidence among subgroups of people with HIV

137 Anal cancer incidence did not correlate with HIV-1 antib

138 W), but are poorly characterized in terms of anal cancer incidence due to absence of reporting of sex

139 ted standardized incidence ratios to compare anal cancer incidence in people with HIV infection with

140 Global anal cancer incidence is increasing.

141 Conclusion Anal cancer incidence is markedly elevated among people

142 Anal cancer incidence is significantly higher in people

143 tiretroviral therapy to HIV-infected people, anal cancer incidence may start to decline.

144 follow-up between 1996 and 2007, we compared anal cancer incidence rates among 34 189 HIV-infected (5

145 Among men, the unadjusted anal cancer incidence rates per 100 000 person-years wer

146 Anal cancer incidence was highest among men who have sex

147 lts Among 447,953 people with HIV infection, anal cancer incidence was much higher than in the genera

148 ART was not associated with anal cancer incidence when adjusted for years living wit

149 e developed a mathematical model to estimate anal cancer incidence, annual number of cases, and propo

150 tological and cytological abnormalities; and anal cancer incidence.

151 high human immunodeficiency virus (HIV) and anal cancer incidence.

152 Risk of anal cancer increased after 1995 (RH = 2.9).

153 Only the relative incidence of anal cancer increased over time.

154 lications in the areas of colon, rectal, and anal cancers; inflammatory bowel disease; incontinence;

155 e of PVOD in the French population that have anal cancer is 3.9 of 1000 patients, which is much highe

156 The main risk factor for anal cancer is a human papillomavirus infection; those w

157 Anal cancer is an example of a rare cancer, with the hum

158 The majority of anal cancer is associated with human papillomavirus (HPV

159 Like cervical cancer, anal cancer is associated with human papillomavirus (HPV

160 Anal cancer is caused by human papillomavirus (HPV), yet

161 Anal cancer is common among people infected with human i

162 High-resolution anoscopy (HRA) to prevent anal cancer is complex and screening capacity is limited

163 infections are common, and the incidence of anal cancer is high in HIV-infected men who have sex wit

164 One of the groups at highest risk of anal cancer is homosexual and bisexual men.

165 Although the primary cause of anal cancer is human papillomavirus (HPV) infection in t

166 The risk of anal cancer is increased among people with HIV, particul

167 The rate of anal cancer is increasing among both women and men, part

168 Human papillomavirus (HPV)-associated anal cancer is increasing in prevalence and is more comm

169 he use of MMC in a definitive CR regimen for anal cancer is justified, particularly in patients with

170 Anal cancer is more common in women than in men, yet lit

171 lthough cervical cancer is a global concern, anal cancer is more important among people living with H

172 The role of cisplatin in anal cancer is not completely clear, although an ongoing

173 Anal cancer is one of the most common cancers affecting

174 As anal cancer is potentially preventable, these important

175 es occurring in the HIV-positive population, anal cancer is potentially preventable, using methods si

176 omavirus (HPV), primarily HPV type 16 or 18, anal cancer is preceded by high-grade anal intraepitheli

177 Similar to cervical cancer, anal cancer is preceded by high-grade squamous intraepit

178 The incidence of anal cancer is substantially higher among persons living

179 incidence of human papillomavirus-associated anal cancer is unacceptably high among HIV-positive men

180 lations who have a higher risk of developing anal cancers is critical to target preventive interventi

181 on, most notably HPV16, the central cause of anal cancer, is increased by anal sexual intercourse and

182 ho have sex with men, are at excess risk for anal cancer, it has been difficult to disentangle the in

183 continue to have high rates of cervical and anal cancer, it is important to continue screening effor

184 ncies, some related to known infections (eg, anal cancer, Kaposi sarcoma) and others unrelated (eg, m

185 men (MSM) with HIV are at increased risk for anal cancer, largely attributable to persistent HPV infe

186 Groups with high cumulative incidence of anal cancer may benefit from screening.

187 gnosis of lung (median, 50 vs. 54 years) and anal cancer (median, 42 vs. 45 years) were significantly

188 ccurring in those having salvage surgery for anal cancer.Multivariable analysis showed R0 resection w

189 Tissue samples of HIV+ men with anal cancer (n = 26), AIN3 (n = 24), AIN2 (n = 42), AIN1

190 19.1% of all male anal cancer occurred in MSM without HIV, increasing from

191 nt smoking was significantly associated with anal cancer (odds ratio (OR) = 2.59, 95% confidence inte

192 E6 antibodies, apart from anti-HPV58 E6 and anal cancer (OR, 6.8; 95% CI, 1.4 to 33.1).

193 cART appears to have no preventive effect on anal cancer, particularly in MSM.

194 h for reducing treatment-related toxicity in anal cancer patients.

195 sed for vulvar/vaginal cancer in families of anal cancer patients.

196 drivalent HPV vaccine (qHPV) reduces risk of anal cancer/precancerous lesions in young men who have s

197 o have sex with men (MSM) without history of anal cancer/precancerous lesions.

198 Cytology screening can detect the anal cancer precursor, anal intraepithelial neoplasia (A

199 mous intraepithelial lesions (LSILs) and the anal cancer precursor, high-grade squamous intraepitheli

200 The anal cancer precursor, high-grade squamous intraepitheli

201 the impact of a screening program to detect anal cancer precursors on the incidence of cases of inva

202 the impact of a screening program to detect anal cancer precursors on the incidence of cases of inva

203 le and clinically relevant methods to detect anal cancer precursors.

204 aepithelial lesions (HSIL) in men can inform anal cancer prevention efforts.

205 For targeted secondary anal cancer prevention in high-risk groups, HIV-negative

206 These findings should inform anal cancer prevention recommendations in male risk grou

207 illomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vaccine effecti

208 onfirming HIV-positive MSM as priorities for anal cancer prevention.

209 a continued structured screening program for anal cancer prevention.

210 Our results are consistent with anal cancer promotion by severe, prolonged HIV-induced i

211 HIV-infected women had an anal cancer rate of 30/100 000 person-years, and no case

212 Anal cancer rates are higher for human immunodeficiency

213 Anal cancer rates declined among men who have sex with m

214 Anal cancer rates have increased, particularly in human

215 Anal cancer rates were substantially higher for HIV-infe

216 Anal cancer rates were substantially higher for HIV-infe

217 With the gradual increase of anal cancer rates, there is a growing need to establish

218 Guidelines for anal cancer recommend assessment of response at 6-12 wee

219 vention of anal intraepithelial neoplasia or anal cancer related to infection with HPV-6, 11, 16, or

220 Anal cancer remains rare (incidence of about 1.5 per 100

221 Cox models, we assessed associations between anal cancer risk and various time-updated CD4 and HIV RN

222 They demonstrate that anal cancer risk is increased in association with a low

223 ly those older than 45 years, have a similar anal cancer risk profile to that of HIV-positive women.

224 he past were generally better predictors for anal cancer risk than their corresponding more recent me

225 human papillomavirus type 16 protein E6 and anal cancer risk, highlighting the role of this viral on

226 screening programmes might help to stratify anal cancer risk, irrespective of HIV status.

227 y virus (HIV; PLWH) have a markedly elevated anal cancer risk, largely due to loss of immunoregulator

228 nd/or HIV-1 RNA level (HIV RNA) best predict anal cancer risk.

229 seful markers for identifying PLWH at higher anal cancer risk.

230 ight reduce anal high-risk HPV infection and anal cancer risk.

231 appear to be important in reducing long-term anal cancer risks.

232 pational exposure of healthcare workers; (5) anal cancer screening among men who have sex with men (M

233 onal analysis of 320 MSM with HIV undergoing anal cancer screening and high-resolution anoscopy (HRA)

234 ers could help refine clinical approaches to anal cancer screening and prevention for the HIV-infecte

235 The advisory group on anal cancer screening and prevention met to formulate ke

236 All HIV-infected adults should be offered anal cancer screening as part of clinical care at specia

237 sease were substantial, supporting universal anal cancer screening for this population.

238 tained from high-risk patients, submitted to anal cancer screening from July 2016 to January 2017.

239 se findings provide important data to inform anal cancer screening guidelines for WHIV.

240 Recently published anal cancer screening guidelines recommend 5 strategies

241 in the cervix show promise as biomarkers for anal cancer screening in HIV+ and at-risk HIV-negative w

242 New data and clinical guidelines support anal cancer screening of people with HIV, but important

243 longitudinal HIV cohort with a comprehensive anal cancer screening program, we estimated the adjusted

244 ological study to evaluate whether access to anal cancer screening programs may help improve patient

245 sidered when selecting the best approach for anal cancer screening programs.

246 HIV-positive MSM are a priority for anal cancer screening research and initiatives targeting

247 Primary anal cancer screening results from this population could

248 Anal cancer screening should be considered for HIV-posit

249 Data are insufficient to recommend routine anal cancer screening with anal cytology in persons livi

250 Using a longitudinal inception cohort of anal cancer screening, we evaluated risk factors and out

251 ave shown promising clinical performance for anal cancer screening.

252 red decision-making conversations concerning anal cancer screening.

253 omarkers may improve the current strategy of anal cancer screening.

254 tertiary dermatological referral center for anal cancer screening.

255 eased risk for HG-AIN+ and should be offered anal cancer screening.

256 detection is a potentially relevant tool for anal cancer screening.

257 o -1.86; P < .001), whereas the incidence of anal cancer significantly increased (APC, 4.42; 95% CI,

258 to use in clinical research and practice for anal cancer since no questionnaire specific for anal can

259 o reduction in the incidence of cervical and anal cancer since the introduction of highly active anti

260 and substantially elevated risks for second anal cancer (SIR = 120.50) and Kaposi's sarcoma (SIR = 1

261 n's disease (SIR = 2.5; 95% CI 1.5-3.9), and anal cancer (SIR = 24.2 95% CI 13.5-39.9).

262 HIV was associated with anal cancer-specific mortality among female patients onl

263 ns between HIV status and both all-cause and anal cancer-specific mortality overall, we used Cox prop

264 Anal cancer-specific mortality was elevated among female

265 Among patients with HIV, anal cancer-specific mortality was increased among patie

266 We aimed to compare all-cause and anal cancer-specific survival in patients with anal canc

267 d cancer survival time with HAART use, while anal cancer survival may have been slightly decreased (R

268 Anal cancer swabs showed highest methylation.

269 n 23 fractions) in patients with early-stage anal cancer; T1-2 (<=4 cm) N0-NxM0.

270 d undetectable HIV PVL had 44% lower risk of anal cancer than those without (adjusted HR 0.56, 0.44-0

271 consequence of staging misclassification in anal cancer that we have termed reduced prognostic discr

272 In US men, the incidence of anal cancer, the primary cause of which is human papillo

273 tizing component of chemoradiation (CRT) for anal cancer; the Expert Panel recognizes that capecitabi

274 The results of our trial--the largest in anal cancer to date--show that fluorouracil and mitomyci

275 s, and estimated the cumulative incidence of anal cancer to measure absolute risk.

276 e in longitudinal follow-up of patients with anal cancer treated with (chemo)radiation, the EORTC-QLQ

277 etabolic tumor volume (MTV) in patients with anal cancer treated with definitive chemoradiotherapy.

278 Domains and codes relevant to anal cancer treatment were selected from interviews to i

279 other HPV-related cancers (e.g. cervical and anal cancer), trends over time do not appear to be influ

280 clear, although an ongoing randomized trial (Anal Cancer Trial II) may help clarify the role of cispl

281 and clinician reporting instruments used in anal cancer trials including radiation treatment.

282 The rate of progression to anal cancer was lower in the treatment group than in the

283 An excess in anal cancer was observed but did not appear to be associ

284 ts with biopsy-proven anal HSIL, the risk of anal cancer was significantly lower with treatment for a

285 In the USA, more than 7200 new cases of anal cancer were diagnosed in 2014 with incidence rising

286 d not received systemic therapy for advanced anal cancer were randomly assigned 1:1 to intravenous ci

287 The IRs for vulvovaginal and anal cancers were also higher in WLWH.

288 Patients with anal cancer who underwent PET imaging for pretreatment s

289 ly been questioned, while the association of anal cancer with AIDS in both males and females is more

290 al cancer-specific survival in patients with anal cancer with and without HIV, stratified by sex, and

291 tracer was observed in liver metastases and anal cancer, with an SUV(max) of 9.1 and 13.9, respectiv

292 the general population had an excess risk of anal cancer, with SIRs of 109.8 (95% CI, 84.6 to 140.3),

293 cancer sites, except vaginal cancer and male anal cancer, with the greatest disparity occurring for v